Semaglutide – Injection

Product Description:

Semaglutide injection is a GLP-1 receptor agonist administered via subcutaneous injection. It mimics the action of incretin hormones to stimulate insulin secretion, suppress appetite, and slow gastric emptying. It is used for obesity treatment and weight management related to type 2 diabetes. Clinical trials have shown an approximate 12–15% reduction in body weight. The medication is approved by the U.S. FDA, the European EMA, and other regulatory agencies. It is administered once weekly and is indicated for adults with BMI ≥ 30, or BMI ≥ 27 with obesity-related comorbidities.

Active Ingredient: Semaglutide
Dosage Form: Subcutaneous injection
Dosing Frequency: Once weekly. Each dose pack contains 4 injections, providing four weeks of treatment.
Brand Name: Wegovy
Generic Name: Semaglo OB
Manufacturer (Generic): Ziska Pharmaceuticals

Indications:

Semaglutide injection is indicated for patients with obesity as an adjunct to diet and exercise to improve glycemic control, support weight management, and reduce the risk of obesity-related complications.

Dosage and Administration:

Administer once weekly via subcutaneous injection. Injection sites include the abdomen, thigh, or upper arm subcutaneous tissue, and sites should be rotated weekly. The starting dose is 0.25 mg weekly for 4 weeks, then gradually increased to 0.5 mg, 1.0 mg, 1.7 mg, and finally up to a maximum dose of 2.4 mg. Each dose level should be maintained for 4 weeks. If well tolerated, the dose may be escalated according to physician guidance. If a dose is missed, administer within 96 hours; otherwise, skip the missed dose and resume the regular schedule.

Side Effects:

Common side effects include nausea, stomach discomfort, indigestion, acid reflux, abdominal pain, bloating, constipation, taste changes, fatigue, and reduced appetite. In rare cases, serious allergic reactions may occur. Side effects vary by individual; close monitoring is advised during the initial treatment phase.

Storage Conditions:

Store in a refrigerator at 2°C to 8°C. Do not freeze. Protect from light and keep out of reach of children. Unopened injections may be stored at room temperature for up to 21 days.

Shipping Information:

This product is shipped directly from the manufacturer and typically arrives in about one week via air transport. Temporary exposure to room temperature during shipping does not affect the medication’s efficacy.

Frequently Asked Questions:

Q: Is the Semaglutide injection sold by Mediva Rx the original brand?
A: No. Mediva Rx provides a generic medication manufactured by one of the top ten pharmaceutical companies in Bangladesh. It contains the same active ingredient and therapeutic effect as the original brand. It has passed DGDA testing and is legally registered for sale.

Q: Is the manufacturer of the Semaglutide generic injection reliable?
A: Yes. Our partner manufacturer, Ziska Pharmaceuticals, is a top-ten pharmaceutical company in Bangladesh, equipped with its own R&D, production lines, and quality-control laboratories. It meets international pharmaceutical manufacturing standards.

Q: Which provides better weight-loss results, Semaglutide or Tirzepatide?
A: According to Eli Lilly’s SURMOUNT-5 Phase 3 clinical trial, Tirzepatide demonstrated superior weight-loss outcomes compared to Semaglutide. Over 72 weeks, patients using Tirzepatide experienced an average weight loss of 20.2% (about 22.8 kg), while Semaglutide resulted in an average weight loss of 13.7% (about 15.0 kg).

Disclaimer:

This information is for reference only. Treatment decisions should follow physician guidance and the official prescribing information.

Prescribing Information:

Download Link